APR 13, 2017 6:00 AM PDT

The Pandora's box of molecular diagnostics: Genomic analysis of uterine lavage fluid detects early endometrial cancers

Speaker
  • Icahn School of Medicine at Mount Sinai Departments of Genetics and Genomic Sciences, Pediatrics, Obstetrics/Gynecology & Reproductive Sciences and Oncological Sciences
    Biography
      John A. Martignetti, MD, PhD, an expert in human genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai, as the Network Director of the Laboratory for Translational Research at the WCHN Biomedical Research Institute. Under this collaboration, Dr. Martignetti's well-established bedside to bench cancer research methodology will be extended to patients at Danbury, Norwalk and New Milford hospitals leading to more personalized and successful therapeutic strategies. He will work closely with the oncology physicians and research scientists across WCHN to build on their nationally recognized efforts.

    Abstract

    Endometrial cancer is the most common gynecologic malignancy in the United States and both the incidence and associated mortality are rising. When detected early, endometrial cancer survival rates are dramatically improved. Despite this, no screening methods have been developed which can effectively detect either pre-malignant lesions or early-stage cancers. We conducted a prospective study to analyze the effectiveness of molecular analysis of uterine lavage fluid, taken at the time of evaluation for a definitive tissue-based diagnosis, to assess the use of targeted next generation sequencing (NGS) for detecting endometrial carcinomas. The women in this study were primarily either experiencing abnormal uterine bleeding or had abnormal pelvic ultrasound findings and were being evaluated by hysteroscopy and curettage for a tissue diagnosis. We detected somatic mutations in all women who were later diagnosed with endometrial cancer, even microscopic stage IA, grade 1. In addition, we also identified that half of the women in our study who did not have clinical evidence of cancer, nonetheless possessed a significant landscape of driver mutations. Our findings therefore suggest the apparently inimicable possibilities of a genomics- based approach for endometrial cancer screening and the discovery of prevalent driver mutations in clinically-defined non-cancerous tissue.


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    MAR 31, 2020 9:00 AM PDT
    C.E. CREDITS
    MAR 31, 2020 9:00 AM PDT
    DATE: March 31, 2020 TIME: 9:00am PT, 12:00pm ET HER2-positive breast cancer is a type of breast cancer caused by over-expression of a protein called human epidermal growth factor receptor 2...
    Loading Comments...
    Show Resources
    Attendees
    • See more